Elektra Health Pricing Analysis & Total Cost

What Elektra Health Actually Charges

Elektra Health operates on a membership model that separates access fees from prescription costs. The membership itself covers provider consultations, care coordination, and educational resources. Prescriptions, lab work, and pharmacy fees sit outside the membership and vary by insurance coverage and medication choice.

The platform has shifted its pricing structure since launch, moving from a purely cash-pay model toward hybrid insurance acceptance. Members on commercial insurance plans accepted by Elektra may pay reduced consultation copays, while cash-pay members absorb the full membership fee plus any medication costs. A single virtual consultation through a menopause specialist outside of a membership model can run $250 to $450 per visit in major metro areas, based on 2024 survey data from the Menopause Society [1]. Elektra's bundled approach aims to undercut that per-visit cost by spreading it across a membership period.

One factor that inflates total cost: lab panels. The North American Menopause Society (NAMS) 2022 position statement recommends baseline hormone panels for women initiating HRT, including FSH, estradiol, and thyroid function tests [1]. These panels cost $100 to $300 at commercial labs if not covered by insurance. Elektra coordinates lab orders but does not absorb the lab fee itself.

Membership Tiers and What Each Includes

Each tier bundles a different number of provider visits, messaging access, and educational content. The base tier typically includes one to two virtual visits per year with asynchronous messaging support. Higher tiers add more frequent synchronous visits, priority scheduling, and dedicated care navigation.

The practical question is whether you need two visits per year or six. For a straightforward menopause hormone therapy initiation, the Endocrine Society's 2015 clinical practice guideline recommends a follow-up visit at 3 months post-initiation, then every 6 to 12 months once stable [2]. That pattern aligns with a mid-tier plan. Women managing complex symptoms (vasomotor symptoms plus genitourinary syndrome plus mood disruption) or those titrating multiple medications may need the higher tier's visit frequency.

Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and medical director of NAMS, has stated: "The goal of menopause hormone therapy is to use the lowest effective dose for the shortest duration consistent with treatment goals" [1]. That clinical principle matters for pricing because it means most women stabilize on a regimen within 6 to 12 months, after which visit frequency (and therefore the value of a higher-tier membership) decreases.

Prescription Costs on Top of Membership

The membership fee is not the full story. Hormone therapy prescriptions represent a separate, sometimes larger cost layer. FDA-approved estradiol patches (such as Climara or Vivelle-Dot) carry retail prices of $150 to $350 per month without insurance, though generic transdermal estradiol drops to $30 to $80 per month at most pharmacies [3]. Oral micronized progesterone (Prometrium) runs $30 to $90 per month for branded, with generics at $10 to $30 [3].

For women using compounded bioidentical hormones, which some menopause platforms promote, costs range from $30 to $200 per month depending on the compounding pharmacy and formulation. The FDA and the Endocrine Society have both cautioned that compounded bioidentical hormones lack the standardized quality controls of FDA-approved products [2]. Elektra's providers generally prescribe FDA-approved formulations, which keeps pharmacy costs within predictable ranges.

A concrete example: a woman initiating transdermal estradiol 0.05 mg/day plus oral micronized progesterone 200 mg nightly (a standard regimen per NAMS guidelines) would pay approximately $40 to $110 per month using generics, or $480 to $1,320 annually for medications alone [1][3]. Add a mid-tier Elektra membership and one external lab panel, and total first-year cost lands between $800 and $1,900.

The WHI (Women's Health Initiative) follow-up data, published in JAMA in 2017 (N=27,347), confirmed that the risk-benefit profile of HRT depends heavily on age at initiation and time since menopause [4]. Women who start HRT within 10 years of menopause onset or before age 60 show cardiovascular benefit rather than harm. This "timing hypothesis" data matters for cost analysis because it supports initiating therapy during a defined window, not indefinitely, which caps the total duration of platform membership expenses.

Insurance Coverage and Out-of-Pocket Reality

Elektra accepts select commercial insurance plans, though the specific panel changes quarterly. For members whose insurance is accepted, consultation copays may replace or reduce the membership fee. Out-of-network members can submit superbills for potential partial reimbursement.

The Affordable Care Act mandates coverage of preventive services for women, including well-woman visits, but menopause-specific consultations and HRT do not fall under the preventive mandate in most plan interpretations [5]. A 2023 Kaiser Family Foundation analysis found that 58% of women ages 50 to 64 reported at least one out-of-pocket barrier to accessing menopause care [5]. This gap is precisely where platforms like Elektra position themselves.

For women on high-deductible health plans (HDHPs), the entire cost of consultations and prescriptions may apply to the deductible. The average individual HDHP deductible reached $2 to 757 in 2023, according to Kaiser Family Foundation data [5]. In that scenario, an Elektra membership that bundles visits at a fixed annual price may actually cost less than paying per-visit rates toward an unmet deductible.

One wrinkle: HSA and FSA eligibility. Membership fees for telehealth platforms may qualify as HSA/FSA-eligible expenses if the platform provides direct clinical care (not just wellness coaching). Elektra's model, which includes licensed prescribers, generally meets that threshold, but members should confirm with their HSA administrator.

How Elektra Compares to Competing Platforms

The menopause telehealth space has expanded rapidly. Direct competitors include Midi Health, Alloy, and Evernow, each with different pricing architectures.

Midi Health operates primarily through insurance billing, accepting most major commercial plans and Medicare. For insured members, out-of-pocket costs are limited to standard copays ($20 to $50 per visit). For uninsured patients, Midi charges per visit. This insurance-first model means Midi's effective cost is lower for women with in-network coverage but potentially higher for cash-pay patients who lack the bundled pricing of a membership.

Alloy uses a direct-to-consumer model focused on product sales. Hormone therapy products are sold as monthly subscriptions ($30 to $85 per month for estradiol or progesterone formulations), with virtual consultations included in the subscription price. Total annual cost at Alloy: approximately $360 to $1,020 for medication plus consultations combined. The trade-off is narrower clinical scope. Alloy focuses on prescribing specific products rather than comprehensive menopause care coordination.

Evernow follows a similar product-subscription model, with monthly costs of $49 to $159 depending on the treatment plan. Annual spend: $588 to $1,908. Evernow includes provider access and medication in a single subscription, which simplifies cost comparison but limits flexibility in pharmacy choice.

A 2020 systematic review in Menopause (the journal of NAMS) found that telehealth delivery of menopause care produced equivalent patient satisfaction scores and symptom improvement compared to in-person visits, across 11 studies involving over 3,000 women [6]. The clinical outcomes appear equivalent across delivery models, which makes pricing and service scope the primary differentiators.

The REPLENISH trial (N=1,835), published in Obstetrics & Gynecology, demonstrated that a combined estradiol/progesterone capsule (TX-001HR, now marketed as Bijuva) reduced moderate-to-severe hot flashes by 73% at 12 weeks versus 49% for placebo [7]. Platforms that prescribe combination products like Bijuva may simplify regimens but at higher medication cost ($200 to $300/month branded), illustrating how formulary differences between platforms directly affect total spend.

Red Flags and Legitimate Concerns

Is Elektra Health legit? Yes, in the sense that it employs licensed healthcare providers who prescribe FDA-approved medications. The platform has been featured in medical and mainstream press, and its clinical advisory board includes menopause-credentialed physicians.

Legitimate concerns center on three areas. First, pricing transparency. Membership costs and what exactly each tier includes have not always been clearly displayed on the website, requiring a consultation or enrollment step to see full pricing. Second, provider continuity. Some membership-based platforms rotate providers across visits, which can fragment care. Third, scope limitations. Complex cases involving surgical menopause, premature ovarian insufficiency, or hormone-sensitive cancer history may require in-person specialist evaluation that falls outside the platform's telehealth scope.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 on management of menopausal symptoms states: "Women with premature or early menopause should be counseled that hormone therapy is recommended at least until the median age of natural menopause (age 51) to reduce long-term health risks" [8]. This guidance implies that women with premature menopause face a longer treatment horizon, potentially 10 to 20 years, and should weigh platform commitment and cost over that extended timeline.

Who Gets the Most Value from Elektra

The cost-benefit equation tips in Elektra's favor for a specific patient profile: women aged 45 to 55 experiencing moderate-to-severe vasomotor symptoms, who lack a menopause-knowledgeable local provider, and whose insurance either is not accepted by Midi Health or carries high deductibles that make per-visit billing expensive.

A 2015 study in Menopause found that only 20% of ob-gyn residency programs included formal menopause education [9]. The resulting provider knowledge gap means many women receive outdated or dismissive responses when seeking menopause care from generalists. For these women, a platform staffed by menopause-focused clinicians may deliver better clinical outcomes per dollar spent.

Conversely, women with straightforward symptoms, good insurance coverage, and access to a menopause-competent local provider may find that a standard office visit ($30 copay) plus generic prescriptions ($10 to $30/month) totals far less than any telehealth membership.

The SWAN study (Study of Women's Health Across the Nation, N=3,302) established that the median duration of vasomotor symptoms is 7.4 years, with 25% of women experiencing symptoms for more than 10 years [10]. That duration shapes the total cost calculation significantly. A $500 annual membership over 7 years totals $3 to 500 in platform fees alone, before medications and labs.

Calculating Your Actual Total First-Year Cost

Start with the membership tier that matches your expected visit frequency. Add one baseline lab panel ($100 to $300). Add 12 months of medication at generic pricing ($40 to $110/month, or $480 to $1,320/year). Subtract any insurance reimbursement or HSA/FSA contributions.

For a mid-tier membership with generic HRT and one lab panel, expect a first-year range of $800 to $1,900 out-of-pocket. Year two and beyond drops by the cost of the initial lab panel and any dose-titration visits, typically settling at $600 to $1,500 annually.

The 2022 Endocrine Society guideline recommends annual mammography for women on HRT, regardless of baseline risk [2]. That screening cost (typically covered by insurance under ACA preventive mandates, but $150 to $300 if uninsured) should be factored into the total annual cost of maintaining any HRT regimen, whether through Elektra or any other provider.